Skip to content
Clinical Research Made Simple

Clinical Research Made Simple

Trusted Resource for Clinical Trials, Protocols & Progress

  • Home
  • Audit Findings
    • General Audit Findings in Clinical Trials
    • Investigator Site-Level Audit Findings
    • Sponsor & CRO-Level Audit Findings
    • Trial Master File (TMF) & eTMF Audit Findings
    • Informed Consent Audit Findings
    • Safety Reporting Audit Findings
    • Data Integrity & EDC Audit Findings
    • GCP Training & Compliance Audit Findings
    • Clinical Trial Supply & IMP Audit Findings
    • Ethics Committee / IRB Audit Findings
    • CAPA & Inspection Readiness Audit Findings
    • Case Studies & Trends in Audit Findings
  • Audits, CAPA & Deviations
    • CRO Audit Oversight
    • CAPA Management in CROs
    • Deviation Handling in CROs
    • Inspection Readiness for CROs
    • Data Integrity & Systems Oversight
    • Training & Quality Culture in CROs
  • SOPs for GCP
    • Global SOPs (Applicable to all Agencies)
    • SOP for IDE/Device
    • FDA — Unique SOPs (United States)
    • EMA — Unique SOPs (European Union)
    • CDSCO/DCGI – Unique SOPs (India)
    • WHO – Unique SOPs
    • ICH – Unique SOPs
    • MHRA — Unique SOPs (United Kingdom)
    • Health Canada — Unique SOPs (Canada)
    • PMDA — Unique SOPs
    • TGA — Unique SOPs
    • NMPA — Unique SOPs
    • ANVISA — Unique SOPs
    • Swiss Medic — Unique SOPs
    • Medsafe/HDEC — Unique SOPs (New Zealand)
  • US Regulatory Submissions
  • Toggle search form

Site Initiation Visit (SIV) Checklist and Objectives for Clinical Trials

Posted on June 14, 2025 digi By digi

Published on 21/12/2025

Comprehensive Guide to Site Initiation Visit (SIV) Checklist and Objectives

The Site Initiation Visit (SIV) marks a critical milestone in the clinical trial start-up process. It signals that a site is ready to begin patient enrollment and that all staff are trained and equipped for protocol adherence and GCP compliance. In this tutorial, we walk through the essential components of the SIV—what it aims to achieve, how to prepare, and what to include in your checklist to ensure a successful site activation.

Table of Contents

Toggle
  • What is a Site Initiation Visit (SIV)?
  • Primary Objectives of the SIV:
  • Pre-SIV Preparation Steps:
  • Detailed SIV Checklist:
  • During the SIV Meeting:
  • Post-SIV Follow-Up:
  • Common Pitfalls to Avoid:
  • Conclusion:

What is a Site Initiation Visit (SIV)?

An SIV is a formal meeting between the sponsor or CRO and the investigational site team conducted after regulatory approvals are in place but before the site begins enrolling subjects.

  • Confirms site readiness for trial initiation
  • Ensures all study staff are trained on protocol and procedures
  • Verifies essential documents, equipment, and IMP availability
  • Resolves any final site queries before activation

Primary Objectives of the SIV:

  • Provide comprehensive training on the protocol and investigational product
  • Ensure understanding of GCP obligations and reporting requirements
  • Verify document completeness and regulatory binder setup
  • Confirm site logistics and delegation of responsibilities
  • Finalize pre-FPI (First Patient In) readiness
See also  How to Develop a Patient Enrollment Plan for Clinical Trials

SIVs are also a compliance checkpoint and often reviewed during sponsor or USFDA audits.

Pre-SIV Preparation Steps:

  1. Send agenda and checklist to
site in advance
  • Verify IRB/EC approval and essential document collection
  • Ensure investigational product shipment and storage validation
  • Confirm access to electronic systems (eCRF, IWRS, CTMS)
  • Review Delegation of Authority Log and staff credentials
  • Using an SIV-specific SOP and templates from Pharma SOPs standardizes the process.

    Detailed SIV Checklist:

    A thorough checklist ensures consistency and completeness. Categories to include:

    1. Protocol Training:

    • Study design, objectives, endpoints, and procedures
    • Inclusion/exclusion criteria with examples
    • Visit schedule and allowable windows
    • Randomization and blinding procedures (if applicable)

    2. Investigational Product (IP) and Accountability:

    • Storage requirements (temperature logs, security)
    • IP receipt, verification, and accountability log
    • Instructions for dispensing and return of unused product
    • Review of pharmacy procedures and unblinding process

    3. Regulatory Documents and IRB Approval:

    • Signed protocol and ICF approvals
    • Updated CVs, GCP certificates, medical licenses
    • Financial disclosure forms
    • Completed 1572 or equivalent forms

    4. Safety and AE/SAE Reporting:

    • Definitions of adverse events and serious adverse events
    • Reporting timelines and contact points
    • Emergency unblinding protocol
    • Safety monitoring committee interactions (if applicable)

    5. Source Documentation and Data Entry:

    • Source documentation expectations
    • Electronic Case Report Form (eCRF) training and demo
    • Query resolution process
    • Audit trail maintenance and version control

    6. Delegation of Authority and Staff Roles:

    • Review of site staff and delegated responsibilities
    • Staff sign-off on protocol and SOPs
    • Contingency planning for staff turnover

    7. Site Logistics and Equipment:

    • Tour of facility (if in-person)
    • Review of lab equipment, centrifuge, storage, and shipping supplies
    • IMP access control and calibration records

    During the SIV Meeting:

    Ensure active participation by:

    • Principal Investigator (PI)
    • Sub-Investigators and Clinical Research Coordinators
    • Pharmacist (if IP is managed onsite)
    • Laboratory contact (if site-managed lab is used)

    Use a sign-in sheet to document attendance for audit purposes.

    Post-SIV Follow-Up:

    1. Share a completed SIV checklist with site and project team
    2. Issue a greenlight letter for activation once all conditions are met
    3. Address outstanding action items, such as missing documents or unresolved queries
    4. Update CTMS and TMF with finalized materials

    Common Pitfalls to Avoid:

    • Insufficient training or rushed protocol review
    • Incomplete regulatory binder or missing signatures
    • Failure to test EDC logins or confirm access
    • IMP not delivered or stored improperly

    Conclusion:

    The Site Initiation Visit is a vital milestone that ensures trial quality from the outset. By using a structured checklist, defining clear objectives, and involving all key personnel, sponsors and CROs can confidently activate sites with full regulatory compliance. Tools and SOP templates from Stability Studies can further streamline your SIV process and documentation workflows.

    Clinical Research Operations, Site Selection and Initiation Tags:clinical trial kickoff visit, clinical trial site readiness, CRA site initiation guide, GCP training SIV, how to conduct SIV, IMP accountability checklist, investigator training checklist, IRB approval confirmation SIV, PI training visit, pre-FPI site visit guide, protocol-specific site training, site activation readiness, site equipment verification, site initiation expectations, site initiation SOPs, site initiation visit checklist, site start-up checklist, SIV documentation, SIV meeting agenda, SIV objectives clinical trials, SIV preparation steps, SIV regulatory compliance, sponsor site visit, sponsor SIV presentation], trial document handover

    Post navigation

    Previous Post: Using Mobile Apps to Improve Trial Retention in Clinical Studies
    Next Post: Blinding Strategies in Multi-Arm Factorial Trials – Clinical Trial Design and Protocol Development

    Quick Guide – 1

    • Clinical Trial Phases (7)
      • Preclinical Studies (25)
      • Phase 0 (Microdosing Studies) (6)
      • Phase 1 (Safety and Dosage) (66)
      • Phase 2 (Efficacy and Side Effects) (54)
      • Phase 3 (Confirmation and Monitoring) (70)
      • Phase 4 (Post-Marketing Surveillance) (79)
    • Regulatory Guidelines (71)
      • U.S. FDA Regulations (14)
      • CDSCO (India) Guidelines (11)
      • EMA (European Medicines Agency) Guidelines (17)
      • PMDA (Japan) Guidelines (1)
      • MHRA (UK) Guidelines (1)
      • TGA (Australia) Guidelines (1)
      • Health Canada Guidelines (1)
      • WHO Guidelines (1)
      • ICH Guidelines (12)
      • ASEAN Guidelines (11)
    • Country-Specific Clinical Trials (254)
      • Clinical Trials in USA (51)
      • Clinical Trials in China (49)
      • Clinical Trials in EU (51)
      • Clinical Trials in India (51)
      • Clinical Trials in UK (51)
      • Clinical Trials in Canada (1)
    • Clinical Trial Design and Protocol Development (106)
      • Randomized Controlled Trials (RCTs) (11)
      • Adaptive Trial Designs (10)
      • Crossover Trials (10)
      • Parallel Group Designs (11)
      • Factorial Designs (11)
      • Cluster Randomized Trials (11)
      • Single-Arm Trials (10)
      • Open-Label Studies (11)
      • Blinded Studies (Single, Double, Triple) (11)
      • Non-Inferiority and Equivalence Trials (8)
      • Randomization Techniques in Crossover Trials (1)
    • Good Clinical Practice (GCP) and Compliance (78)
      • GCP Training Programs (11)
      • ICH-GCP Compliance (11)
      • GCP Violations and Audit Responses (11)
      • Monitoring Plans (11)
      • Investigator Responsibilities (11)
      • Sponsor Responsibilities (11)
      • Ethics Committee Roles (11)
    • Clinical Research Operations (44)
      • Study Start-Up Activities (9)
      • Site Selection and Initiation (10)
      • Patient Enrollment Strategies (13)
      • Data Collection and Management (10)
      • Monitoring and Auditing (1)
      • Study Close-Out Procedures (0)
    • Site Management and Monitoring (72)
      • Site Feasibility Assessments (20)
      • Site Initiation Visits (10)
      • Routine Monitoring Visits (10)
      • Source Data Verification (12)
      • Site Close-Out Visits (10)
      • Site Performance Metrics (10)
    • Contract Research Organizations (CROs) (55)
      • Full-Service CROs (11)
      • Functional Service Providers (FSPs) (10)
      • Niche/Specialty CROs (11)
      • CRO Selection Criteria (11)
      • CRO Oversight and Management (11)
    • Patient Recruitment and Retention (57)
      • Recruitment Strategies (11)
      • Retention Strategies (11)
      • Patient Engagement Tools (11)
      • Diversity and Inclusion in Trials (11)
      • Use of Social Media for Recruitment (12)
    • Informed Consent and Ethics Committees (54)
      • Informed Consent Process (11)
      • Ethics Committee Submissions (10)
      • Ethical Considerations in Vulnerable Populations (11)
      • Consent in Emergency Research (10)
      • Re-Consent Procedures (11)
    • Decentralized Clinical Trials (DCTs) (55)
      • Remote Patient Monitoring (10)
      • Telemedicine in Trials (11)
      • Home Health Visits (11)
      • Direct-to-Patient Drug Delivery (11)
      • Digital Consent Platforms (11)
    • Clinical Trial Supply and Logistics (55)
      • Investigational Product Management (11)
      • Cold Chain Logistics (10)
      • Supply Chain Risk Management (11)
      • Labeling and Packaging (11)
      • Return and Destruction of Supplies (11)
    • Safety Reporting and Pharmacovigilance (56)
      • Adverse Event Reporting (11)
      • Serious Adverse Event (SAE) Management (11)
      • Safety Signal Detection (11)
      • Risk Management Plans (11)
      • Periodic Safety Update Reports (PSURs) (11)
    • Clinical Data Management (57)
      • Case Report Form (CRF) Design (11)
      • Data Entry and Validation (11)
      • Query Management (11)
      • Database Lock Procedures (11)
      • Data Archiving (12)
    • Biostatistics in Clinical Research (57)
      • Statistical Analysis Plans (11)
      • Sample Size Determination (11)
      • Interim Analysis (11)
      • Survival Analysis (12)
      • Handling Missing Data (11)
    • Real-World Evidence (RWE) and Observational Studies (56)
      • Registry Studies (11)
      • Retrospective Chart Reviews (11)
      • Prospective Cohort Studies (11)
      • Case-Control Studies (11)
      • Use of Electronic Health Records (EHRs) (11)
    • Medical Writing and Study Documentation (58)
      • Protocol Writing (11)
      • Investigator Brochures (11)
      • Clinical Study Reports (CSRs) (11)
      • Manuscript Preparation (11)
      • Regulatory Submission Documents (13)
    • Trial Master File (TMF) Management (57)
      • TMF Structure and Contents (10)
      • Electronic TMF Systems (7)
      • TMF Quality Control (12)
      • Inspection Readiness (12)
      • Archiving Requirements (11)
    • Protocol Amendments and Version Control (45)
      • Amendment Classification (11)
      • Regulatory Submissions of Amendments (11)
      • Communication of Changes to Sites (11)
      • Version Control Systems (11)
    • Data Integrity and ALCOA+ Principles (46)
      • Attributable, Legible, Contemporaneous, Original, Accurate (ALCOA) (12)
      • Complete, Consistent, Enduring, and Available (ALCOA+) (10)
      • Data Governance Policies (12)
      • Audit Trails (11)
    • Investigator and Site Training (44)
      • Investigator Meetings (11)
      • Site Staff Training Programs (11)
      • Training Documentation (11)
      • Continuing Education Requirements (10)
    • Budgeting and Financial Management (40)
      • Budget Development (10)
      • Site Payment Management (10)
      • Financial Forecasting (10)
      • Cost Tracking and Reporting (10)
    • AI, Big Data, and Technology in Clinical Trials (41)
      • AI in Patient Recruitment (10)
      • Machine Learning for Data Analysis (10)
      • Blockchain for Data Security (10)
      • Wearable Devices and Sensors (11)
    • Career in Clinical Research (52)
      • Clinical Research Coordinator (CRC) Roles (11)
      • Clinical Research Associate (CRA) Roles (10)
      • Data Manager Careers (10)
      • Biostatistician Roles (10)
      • Regulatory Affairs Careers (11)
    • Clinical Trial Registries and Result Disclosure (40)
      • ClinicalTrials.gov Registration (9)
      • EudraCT Registration (10)
      • Results Posting Requirements (10)
      • Transparency Initiatives (11)

    Quick Guide – 2

    • Clinical Trial Operations & Data Integrity (31)
      • TMF & eTMF (10)
      • Study Operations & Enrollment (10)
      • Biostats, CDISC & Traceability (11)
    • Clinical Trial Operations & Compliance (54)
      • Clinical Trial Logistics (30)
      • TMF / eTMF Management (6)
      • Clinical Trial Phases & Design (6)
      • Regulatory Submissions (CTD/eCTD) (6)
      • Vendor Oversight & CRO Compliance (6)
    • Quality Assurance and Audit Management (40)
      • Internal Audits (10)
      • External Audits (10)
      • Audit Preparation (10)
      • Corrective and Preventive Actions (CAPA) (10)
    • Risk-Based Monitoring (RBM) (40)
      • Risk Assessment Tools (10)
      • Centralized Monitoring Techniques (10)
      • Key Risk Indicators (KRIs) (10)
      • Key Risk Indicators (KRIs) (10)
    • Standard Operating Procedures (SOPs) (39)
      • SOP Development (9)
      • SOP Training (10)
      • SOP Compliance Monitoring (10)
      • SOP Revision Processes (10)
    • Electronic Data Capture (EDC) and eCRFs (40)
      • EDC System Selection (10)
      • eCRF Design (10)
      • Data Validation Rules (10)
      • User Access Management (10)
    • Wearables and Digital Endpoints (35)
      • Integration of Wearable Devices (10)
      • Digital Biomarkers (9)
      • Data Collection and Analysis (7)
      • Regulatory Considerations (9)
    • Blockchain and Data Security in Trials (39)
      • Blockchain Applications in Clinical Research (10)
      • Data Encryption Methods (9)
      • Access Control Mechanisms (11)
      • Compliance with Data Protection Regulations (9)
    • Biomarkers and Companion Diagnostics (39)
      • Biomarker Identification (10)
      • Validation Processes (10)
      • Companion Diagnostic Development (9)
      • Regulatory Approval Pathways (10)
    • Pediatric and Geriatric Clinical Trials (55)
      • Ethical Considerations (11)
      • Age-Specific Protocol Design (22)
      • Dosing and Safety Assessments (11)
      • Recruitment Strategies (11)
    • Oncology Clinical Trials (54)
      • Phase-Specific Oncology Trials (10)
      • Immunotherapy Studies (14)
      • Biomarker-Driven Trials (10)
      • Basket and Umbrella Trials (8)
      • Cancer Vaccines (12)
    • Vaccine Clinical Trials (40)
      • Phase I–IV Vaccine Trials (10)
      • Immunogenicity Assessments (10)
      • Cold Chain Requirements (10)
      • Post-Marketing Surveillance (10)
    • Rare and Orphan Disease Trials (186)
      • Patient Recruitment Challenges (31)
      • Regulatory Incentives (10)
      • Adaptive Trial Designs (10)
      • Natural History Studies (10)
      • Regulatory Frameworks (22)
      • Trial Design & Methodology (22)
      • Operational Challenges (21)
      • Ethics & Patient Engagement (20)
      • Data & Technology (20)
      • Case Studies & Breakthroughs (20)
    • Bioavailability and Bioequivalence Studies (BA/BE) (41)
      • Study Design Considerations (11)
      • Analytical Method Validation (10)
      • Statistical Analysis Requirements (10)
      • Regulatory Submission (10)
    • Regulatory Submissions and Approvals (73)
      • IND (Investigational New Drug) Submissions (10)
      • CTA (Clinical Trial Application) (10)
      • NDA/BLA/MAA Filings (10)
      • ANDA for Generics (10)
      • eCTD Submission Process (2)
      • Pre-Submission Meetings (FDA Type A/B/C) (10)
      • Regulatory Query Response Handling (10)
      • Post-Approval Commitments (11)
    • Clinical Trial Transparency and Ethics (60)
      • Trial Disclosure Obligations (10)
      • Result Publication Requirements (10)
      • Ethical Review Standards (10)
      • Open Access Data Sharing (10)
      • Informed Consent Disclosure (10)
      • Ethical Dilemmas in Global Research (10)
    • Protocol Deviation and CAPA Management (50)
      • Major vs Minor Deviations (10)
      • Root Cause Analysis (9)
      • CAPA Documentation (9)
      • Preventive Action Planning (1)
      • Monitoring and Training Based on Deviations (10)
      • Deviation Logs and Tracking Tools (11)
    • Audit Trails and Inspection Readiness (59)
      • TMF and eTMF Audit Trails (10)
      • Audit Trail Reviews in EDC (10)
      • Inspection Preparation Checklists (10)
      • Regulatory Inspection Types (Routine, For-Cause) (10)
      • Responding to Audit Observations (9)
      • Mock Inspections and Readiness Drills (10)
    • Study Feasibility and Site Selection (68)
      • Feasibility Questionnaire Design (10)
      • Site Capability Assessment (11)
      • Historical Performance Review (17)
      • Geographic and Demographic Considerations (10)
      • PI (Principal Investigator) Experience Evaluation (10)
      • Site Activation Planning (10)
    • Outsourcing and Vendor Management (65)
      • Vendor Qualification Process (12)
      • Due Diligence and Risk Assessment (11)
      • Vendor Contract Management (12)
      • KPIs for Vendor Performance (10)
      • Vendor Oversight and Audits (10)
      • Communication and Escalation Plans (10)
    • Remote Monitoring and Virtual Visits (64)
      • Centralized Monitoring Techniques (12)
      • Source Data Review Remotely (12)
      • Virtual Site Visits Protocols (11)
      • eConsent and Remote Data Collection (10)
      • Hybrid Monitoring Models (10)
      • Remote Site Training (9)
    • Laboratory and Sample Management (77)
      • Sample Collection SOPs (10)
      • Sample Labeling and Transport (10)
      • Chain of Custody Documentation (11)
      • Bioanalytical Testing and Storage (15)
      • Central vs Local Labs (11)
      • Laboratory Data Reconciliation (20)
    • Adverse Event Reporting and Management (63)
      • AE vs SAE Differentiation (10)
      • Expedited Reporting Timelines (11)
      • MedDRA Coding of Events (11)
      • AE Data Collection in eCRFs (11)
      • Causality and Severity Assessments (10)
      • Regulatory Reporting Requirements (CIOMS, SUSARs) (10)
    • Interim Analysis and Trial Termination (60)
      • Data Monitoring Committees (DMC) (10)
      • Pre-Specified Stopping Rules (10)
      • Statistical Thresholds for Early Stopping (10)
      • Adaptive Modifications Based on Interim Data (10)
      • Unblinding Protocols (10)
      • Reporting of Early Termination to Regulators (10)

    Recent Posts

    • Test
    • Comprehensive Guide to Dental Health Care with Braces
    • Understanding Dental Health Care: Managing Implants Cost Effectively
    • Invisalign Alternatives: Practical Dental Health Care Solutions
    • Practical Guide to Dental Health Care: Managing Braces Effectively

    Copyright © 2026 Clinical Research Made Simple.

    Powered by PressBook WordPress theme